drugset / Trial / NCT02238496
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow. Research suggests that combined treatment with both drugs is better than either alone, and that it is reasonably safe.
Timeline
- Start
- 2014-12-08
- Primary completion
- 2017-10-27
- Completion
- 2021-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perifosine | Small molecule | — | Oral |
| Subject | Temsirolimus | Small molecule | — | Intravenous |